Baseline charateristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO)

Clinical and Experimental Rheumatology

Volumn 29, Issue 3, 2011, Pages 477-484

  Adami, S ^a   Maugeri, D ^b   Toscano, V ^c   Topa, G ^d   Caminiti, M ^d   Brancati, A ^e   Massarotti, M ^f   Osella, G ^g   Malavolta, N ^h   Iolascon, G ⁱ   Cagnoni, C ^j   Camozzi, V ^k   Corradini, C ^l   Nardi, A ^m   Migliaccio, S ^n,o   Ulivieri, F M ^p   Resmini, G ^q   Valle, D ^r   Tauchmanova, L ^r   Silvestri, Sandra ^r  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b CANNIZZARO HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^e INRCA   (Italy)

^f HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^g SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ SECOND UNIVERSITY OF NAPLES   (Italy)

^j Azienda USL di Piacenza   (Italy)

^k UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^l UNIVERSITY OF MILAN   (Italy)

^m Ospedale S Maria della Misericordia   (Italy)

ⁿ SAPIENZA UNIVERSITY OF ROME   (Italy)

^o UNIVERSITY OF ROME FORO ITALICO   (Italy)

^p FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^q TREVIGLIO HOSPITAL   (Italy)

^r Eli Lilly Italia   (Italy)

more..

Author keywords

Back pain; Fractures; Observational study; Osteoporosis; Quality of life; Risk factors; Treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; THYROID HORMONE; VITAMIN D; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BACKACHE; BODY MASS; BONE DENSITY; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COMORBIDITY; CORRELATION ANALYSIS; DAILY LIFE ACTIVITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; OBSERVATIONAL STUDY; OSTEOPOROSIS; PAIN ASSESSMENT; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RISK FACTOR; SMOKING; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; CLINICAL TRIAL; COHORT ANALYSIS; HOSPITALIZATION; INCIDENCE; INFORMATION PROCESSING; ITALY; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SPINE FRACTURE;

AGED; AGED, 80 AND OVER; BACK PAIN; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DATA COLLECTION; FEMALE; FRACTURES, BONE; HUMANS; INCIDENCE; ITALY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPINAL FRACTURES; TERIPARATIDE;

EID: 80052051167     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Osteoporosis prevention, diagnosis, and therapy consensus statement 2000. JAMA 2001; 285: 785-795
2. SAMBROOK P., COOPER C.: Osteoporosis. Lancet 2006; 367: 2010-2018
3. WORLD HEALTH ORGANIZATION: Assessment of fracture risk and its application to screening for post-menopausal osteoporosis, Technical report series, WHO, Geneva, 1994.
4. CUMMINGS S.R., BLACK D.M., NEVITT M.C. et al.: Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993; 341: 72-75
5. HUI S.L., SLEMENDA C.W., CAREY M.A., JOHNSTON CC J.R.: Choosing between predictors of fractures. J Bone Miner Res 1995; 10: 1816-1822
6. CUMMINGS S.R., BLACK D.M., NEVITT M.C. et al.: Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA 1990; 263: 665-668
7. BLACK D.M., CUMMINGS S.R., GENANT H.K., NEVITT M.C., PALERMO L., BROWNER W.: Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992; 7: 633-638
8. LINDSAY R., SILVERMAN S.L., COOPER C. et al.: Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-323
9. KLOTZBUECHER C.M., ROSS P.D., LANDSMAN P.B., ABBOTT T.A. 3RD, BERGER M: Patients with prior fractures have an increased risk of future fractures: A summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721-739
10. VAN HELDEN S., CALS J., KESSELS F., BRINK P., DINANT G.J., GEUSENS P.: Risk of new clinical fractures within 2 years following a fracture. Osteoporos Int 2006; 17: 348-354
11. HOES J.N., JACOBS J.W., HULSMANS H.M. et al.: High incidence rate of vertebral fractures during chronic prednisone treatment, in spite of bisphosphonate or alfacalcidol use. Extension of the Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis-trial. Clin Exp Rheumatol 2010; 28: 354-359
12. KADO D.M., BROWNER W.S., PALERMO L., NEVITT M.C., GENANT H.K., CUMMINGS S.R.: Vertebral fractures and mortality in older women: A prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999; 159: 1215-1220
13. CAULEY J.A., THOMPSON D.E., ENSRUD K.C., SCOTT J.C., BLACK D.: Risk of mortality following clinical fractures. Osteoporos Int 2000; 11: 556-561
14. TENG G.G., CURTIS J.R., SAAG K.G.: Mortality and osteoporotic fractures: Is the link causal, and is it modifiable? Clin Exp Rheumatol 2008; 26: S125-S137
15. NEER R.M., ARNAUD C.D., ZANCHETTA J.R. et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441
16. LINDSAY R., MILLER P., POHL G., GLASS E.V., CHEN P., KREGE J.H.: Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int 2009; 20: 943-948
17. KAUFMAN J.M., ORWOLL E., GOEMAERE S. et al.: Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy. Osteoporos Int 2005; 16: 510-516
18. ORWOLL E.S., SCHEELE W.H., PAUL S. et al.: The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18: 9-17.
19. AIFA 2006-2007: Notes for the appropriate use of medicinal products. Official Gazette 2007; Suppl. 7: 61.
20. MINISTRY OF HEALTH: AIFA. Guidelines for the conduct of observational studies. Ministry of Health 2007, item 3; http://www.agen-ziafarmaco.it./ ATTUALITA/section24be.html.
21. BLACK D.M., STEINBUCH M., PALERMO L. et al.: An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001; 12: 519-528
22. BROOKS R.: EuroQol: The current state of play. Health Policy 1996; 37: 53-72.
23. EuroQoL - A new facility for the measurement of health- Related quality of life. The EuroQol Group. Health Policy 1990; 16: 199-208.
24. SZENDE A, WILLIAMS A (Eds.) Measuring self-reported population health: an international perspective based on EQ-5D. ISBN 963 94 56 470. Spring Med Publishing Ltd, 2004SB
25. GOODMAN S.B., JIRANEK W., PETROW E., YASKO A.W.: The effects of medications on bone. J Am Acad Orthop Surg 2007; 15: 450-460
26. RAJZBAUM G., JAKOB F., KARRAS D. et al.: Characterization of patients in the European Forsteo Observational Study (EFOS): Postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 2008; 24: 377-384
27. LIPS P., VAN SCHOOR N.M.: Quality of life in patients with osteoporosis. Osteoporos Int 2005; 16: 447-455
28. BRENNEMAN S.K., BARRETT-CONNOR E., SAJJAN S., MARKSON L.E., SIRIS E.S.: Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006; 21: 809-816
29. OLEKSIK A.M., EWING S., SHEN W., VAN SCHOOR N.M., LIPS P: Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos lnt 2005; 16: 861-70.
30. COCKERILL W., LUNT M., SILMAN A.J. et al.: Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 2004; 15: 113-119